Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat

Neuropharmacology

Volumn 37, Issue 1, 1998, Pages 25-36

  Simmons, Rosa Maria A ^a   Li, Dominic L ^a   Hoo, Ken H ^b   Deverill, Michelle ^b   Ornstein, Paul L ^a   Iyengar, Smriti ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NPS Pharmaceutical Inc   (United States)

Author keywords

AMPA; Competitive non NMDA receptor antagonists; Formalin test; Kainate; Kainate receptor antagonists; Nociception; Non competitive AMPA receptor antagonists

Indexed keywords

2,3 DIBENZODIAZEPINE; 6 (4 CARBOXYBENZYL) 1,2,3,4,4A,5,6,7,8,8A DECAHYDRO 3 ISOQUINOLINECARBOXYLIC ACID; 6 [(4 CARBOXYPHENYL)METHYL 1,2,3,4,4A,5,6,7,8,8A DECAHYDROISOQUINOLINE 3 CARBOXYLIC ACID]; 6 [[(1H 1,2,4 TRIAZOL 5 YLSULFONYL)METHYL] 1,2,3,4,4A,5,6,7,8,8A DECAHYDROISOQUINOLINE 3 CARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; FORMALDEHYDE; GLUTAMATE RECEPTOR ANTAGONIST; LY 302679; LY 302680; N METHYL DEXTRO ASPARTIC ACID; TALAMPANEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BINDING COMPETITION; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STEREOCHEMISTRY;

ANIMALS; BENZODIAZEPINES; EXCITATORY AMINO ACID ANTAGONISTS; FORMALDEHYDE; HUMANS; ISOQUINOLINES; MALE; PAIN THRESHOLD; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, KAINIC ACID; TETRAZOLES;

EID: 0031862305     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00188-3     Document Type: Article

References (40)

1. Abbott F.V., Franklin K.B.J., Westbrook R.F. The formalin test: scoring properties of the first and second phases of the pain response in rats. Pain. 60:1995;91-102.
2. Bleakman D., Ballyk B.A., Schoepp D.D. et al. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereopsecificity and selectivity profiles. Neuropharmacology. 35:1996a;1689-1702.
3. Bleakman D., Schoepp D. D., Ballyk B. et al. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquin oline-3 carboxylic-acid. Mol. Pharmacol. 49:1996b;581-585.
4. Bleisch T.J., Ornstein P.L., Allen N.K., Wright R.A., Lodge D., Schoepp D.D. Structure-activity studies of aryl-spaced decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. Biomed. Chem. Lett. 7:1997;1161-1166.
5. Chizh B.A., Cumberbatch M.J., Headley P.M. A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord. Br. J. Pharmacol. 112:1994;843-846.
6. Coderre T.J., Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J. Neurosci. 12:1992;3665-3670.
7. Coderre T.J., Katz J., Vaccarino A.L., Melzack R. Contribution of central plasticity to to pathological pain: review of clinical and experimental evidence. Pain. 52:1993a;259-285.
8. Coderre T.J., Fundytus M.E., McKenna J.E., Dalal S., Melzack R. The formalin test: a validation of the weighted-scores method of the behavioral pain rating. Pain. 54:1993b;43-50.
9. Coderre T.J., Yashpal K. Intracelullar messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur. J. Neurosci. 6:1994;1328-1334.
10. Cumberbatch M.J., Chizh B.A., Headley P.M. AMPA receptors have an equal role in spinal nociceptive and non-nociceptive transmission. Neuroreport. 5:1994;877-880.
11. Davies S.N., Lodge D. Evidence for the involvement of N-methylaspartate receptors in wind-up of class 2 neurons in the dorsal horn of rat. Brain Res. 424:1987;402-406.
12. Dickenson A.H., Sullivan A.F. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurons following C fibre stimulation. Neuropharmacology. 26:1987;1235-1238.
13. Donevan S.D., Rogawski M.A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective non-competitive antagonist of AMPA/Kainate receptor responses. Neuron. 10:1993;51-59.
14. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidin and brain stem stimulation in rats and cat. Pain. 4:1977;161-174.
15. Dunnett C.W. New tables for multiple comparisons with a control. Biometrics. 20:1964;482-491.
16. Evans R.H., Long S.K. Primary afferent depolarization in the rat spinal cord is mediated by pathways utilizing NMDA and non-NMDA receptors. Neurosci. Lett. 100:1989;231-236.
17. Evans R.H., Evans S.J., Pook P.C., Sunter D.C. A comparison of excitatory amino acid antagonists acting at primary afferent C fibers and motoneurons of the isolated spinal cord of the rat. Br. J. Pharmacol. 91:1987;531-537.
18. Haley J.E., Sullivan A.F., Dickenson A.H. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Res. 518:1990;218-226.
19. Heapy C.G., Jamieson A., Russell N.J.W. Afferent C-fiber and A-delta activity in models of inflammation. Br. J. Pharmacol. 90:1987;164P.
20. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 17:1994;31-108.
21. Honore T., Davies S.N., Fletcher E.J., Jacobsen P., Lodge D., Nielsen F.E. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science. 241:1988;701-703.
22. Huettner J.E. Glutamate receptor channels in DRG neurons: activation of kainate and quisqualate and blockade of desensitization by concavalin. A. Neuron. 5:1990;255-266.
23. Hunskaar S., Hole K. The formalin test: dissociation between inflammatory and non-inflammatory pain. Pain. 30:1987;103-114.
24. Hunter J.C., Singh L. Role of excitatory amino acid receptors in the mediation of the nociceptive response to formalin in the rat. Neurosci. Lett. 174:1994;217-221.
25. Ornstein P.L., Arnold M.B., Augenstein N.K., Lodge D., Leander J.D., Schoepp D.D. 3SR, 4aRS, 6RS, 8aRS)-6-[2-(1H-tetrazol-5-yl) ethyl-decahydroisoquinoline-3-carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. J. Med. Chem. 36:1993;2046-2048.
26. Ornstein P.L., Arnold B.M., Allen N.K. et al. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists, 1. effects of stereochemistry, chain length and chain substitution. J. Med. Chem. 39:1996a;2219-2231.
27. Ornstein P.L., Arnold B.M., Allen N.K. et al. Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic Acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences and in vivo activity. J. Med. Chem. 39:1996b;2232-2244.
28. Palmer A.J., Lodge D. Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655. Eur. J. Pharmacol. 244:1993;193-194.
29. Partin K.M., Patneau D.K., Winter C.A., Mayer M.L., Buonanno A. Selective modulation of desensitization at AMPA versus kainate receptors by cyclothiazide and concanavalin. A. Neuron. 11:1993;1069-1082.
30. Paternain A.V., Morales M., Lerma J. Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron. 14:1995;185-189.
31. Sang C.N., Hostetter M., Gracely R. et al. Analgesic effects of AMPA/kainate antagonist LY293558 in humans: reduction of capsaicin-evoked allodynia and hyperalgesia but not pain sensations in normal skin. Soc. Neurosci. Abstr. 23:1997;1015.
32. Schoepp D.D., Lodge D., Bleakman D. et al. In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1(2)H-Tetrazyl)-5-yl)ethyl]decahydro-isoqui noline-3-carboxylic acid. Neuropharmacology. 34:1995;1159-1168.
33. Seeburg P.H. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci. 16:1993;359-365.
34. Sheardown M.J., Nielson E.O., Jacobson P., Honore T. 2:3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F)quinoxaline:a neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
35. Shibata M., Ohkubo T., Takahashi H., Inoki R. Modified formalin test: Characteristic biphasic pain response. Pain. 38:1989;347-352.
36. Tarnawa I., Berzsenyi P., Andrási F., Botka P., Hámori T., Ling I., Körösi J. Structure-activity relationships of 2,3, benzodiazepine compounds with glutamate antagonistic action. Biorganic Med. Chem. Lett. 3:1993;99-104.
37. Urban L., Thompson S.W.N., Dray A. Modulation of spinal excitability; co-operation between neurokinin and excitatory amino-acid neurotransmitters. Trends Neurosci. 17:1994;432-438.
38. Wheeler-Aceto H., Porreca F., Cowan A. The rat paw formalin test: comparison of noxious agents. Pain. 40:1990;229-238.
39. Woolf C.J., Thompson S.W.N. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: implications for post-injury pain hypersensitivity states. Pain. 44:1991;293-299.
40. Zorumski C.F., Yamada K.A., Price M.T., Olney J.W. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron. 10:1993;61-67.